Literature DB >> 11742248

Defective Fas ligand production in lymphocytes from MS patients.

B Macchi1, C Matteucci, U Nocentini, S Tacconi, V Pagnini, A Mastino, C Caltagirone.   

Abstract

In the present transectional study, Fas ligand (Fas-L) levels, either in membrane or in soluble form, in cells from multiple sclerosis (MS) patients were investigated. Expression of Fas was evaluated after PHA stimulation of peripheral blood mononuclear cells from MS patients with relapsing-remitting or secondary-progressive disease, and in healthy donors. There was statistically significant decreased expression (p = 0.001), as well as release of Fas-L, (p = 0.045) in lymphocytes from MS patients, in comparison with healthy donors. Moreover, levels of Fas-L production were inversely correlated with the EDSS scores of patients in an highly significant way. Impairment of Fas-L release in stimulated PBMC from MS patients might influence the ability to eliminate autoreactive clones in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11742248     DOI: 10.1097/00001756-200112210-00050

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  4 in total

1.  Atorvastatin does not alter serum levels of sCD95 and sCD95L in multiple sclerosis.

Authors:  J Sellner; I Greeve; O Findling; D Grandgirard; S L Leib; H P Mattle
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

2.  FAS-ligand regulates differential activation-induced cell death of human T-helper 1 and 17 cells in healthy donors and multiple sclerosis patients.

Authors:  M T Cencioni; S Santini; G Ruocco; G Borsellino; M De Bardi; M G Grasso; S Ruggieri; C Gasperini; D Centonze; D Barilá; L Battistini; E Volpe
Journal:  Cell Death Dis       Date:  2015-05-07       Impact factor: 8.469

Review 3.  Fas-Fas Ligand: Checkpoint of T Cell Functions in Multiple Sclerosis.

Authors:  Elisabetta Volpe; Manolo Sambucci; Luca Battistini; Giovanna Borsellino
Journal:  Front Immunol       Date:  2016-09-27       Impact factor: 7.561

4.  Programmed cell death and natural killer cells in multiple sclerosis: new potential therapeutic targets?

Authors:  Beatrice Macchi; Antonio Mastino
Journal:  Neural Regen Res       Date:  2016-05       Impact factor: 5.135

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.